SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Acquisition

29 Aug 2006 07:01

Tristel PLC29 August 2006 For release29 August 2006 Tristel Plc Technology Acquisition Agreement with IVC Limited, New Zealand Tristel plc ("Tristel"), the chlorine dioxide specialist that supplies infectionand contamination control products to healthcare and institutionalestablishments and the pharmaceutical and food processing industries, announcesthat it has entered into a technology acquisition agreement with IVC Limited, ("IVC"). IVC is Tristel's New Zealand distributor and its principal shareholderis Mark Fraundorfer, an internationally renowned Urologist. Under the terms of the agreement IVC transfers to Tristel the design and patentrights to two inventions which it has created to work specifically withTristel's chlorine dioxide chemistry. The inventions are a sterilizing traysystem which enables single use decontamination of endoscopic equipment and ahygiene work station which enables Tristel's highly effective sporicidalchemistry to be easily applied to floors and walls in high risk wards anddepartments of hospitals. IVC has funded the design and development process to date and transfers theintellectual property created in return for unspecified future royalties. Commenting upon the agreement, Paul Swinney, Chief Executive of Tristel, said: "Outside of the most advanced healthcare markets, where endoscopes are mainlyprocessed in sophisticated and costly automated machines, the majority ofendoscopes are disinfected in basic trays and sinks. These can only holddisinfectant liquids that have to be used repeatedly for many instruments over aperiod of many hours or even days. "The Tristel tray system, combined with Tristel's novel burstable sachet,Tristel Fusion, enables the disinfectant to be used once and to be dedicated toone instrument only. "This achieves one of the key features of the most sophisticated endoscopereprocessing machines at a fraction of their cost, and will help Tristelpenetrate many overseas markets with its chlorine dioxide disinfectants." Tristel plc Parkgreen Communications Ltd Paul Swinney, Chief Executive Paul McManusPaul Barnes, Finance Director Tel 020 7493 3716Tel: 01638 721 500 Mob: 07980 541 893http://www.tristel.com paul.mcmanus@parkgreenmedia.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM
12th Dec 20227:00 amRNSAGM Statement
2nd Nov 20221:50 pmRNSHolding(s) in Company
25th Oct 20227:00 amRNSAudited Preliminary Results
6th Oct 20229:15 amRNSIssue of Equity
4th Oct 202212:00 pmRNSAppointment of new Company Secretary
4th Oct 20227:00 amRNSNotice of Results & Investor Presentation
29th Sep 20221:00 pmRNSNorth America update
30th Aug 20227:00 amRNSHolding(s) in Company
22nd Jul 20221:05 pmRNSDirector/PDMR Shareholding
21st Jul 202210:15 amRNSHolding(s) in Company
18th Jul 20224:41 pmRNSSecond Price Monitoring Extn
18th Jul 20224:35 pmRNSPrice Monitoring Extension
18th Jul 20227:00 amRNSTrading update and special dividend
30th Jun 20227:00 amRNSDe Novo FDA submission for Tristel Duo ULT
20th Jun 202210:00 amRNSShareholder Open Day & Notice of Trading update
7th Jun 20221:15 pmRNSHolding(s) in Company
4th May 20227:00 amRNSInvestor Presentation
3rd May 202212:30 pmRNSHolding(s) in Company
14th Apr 202212:00 pmRNSIssue of Equity
6th Apr 202212:10 pmRNSDirector/PDMR Shareholding
5th Apr 20222:45 pmRNSDirector/PDMR Shareholding
29th Mar 20223:40 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.